MRNA
Moderna, Inc. Common Stock
stock NASDAQ

Right on. ...going back to pharma (and the associated TAM), MRNA, Moderna, has been good to me in the last few months. They literally have cancer cures (amongst others) in the pipeline, and should outperform once the market starts pricing them as more than a COVID treatment. Similarly, NTRA, Natera, has some interesting DNA diagnostics. Getting a bit pricey, but I'm willing to at least hold until Druckmiller sells.

MRNA

MRNA looking hotter than two mice fucking in a wool sock

MRNA

Moderna MRNA

Huge volume spike on MRNA at 2 damn

Hey degenerates and biotech bulls! I’ve been digging into penny plays, and holy shit, BioVaxys Technology Corp. ($BVAXF OTCQB, $BIOV.CN CSE, FRA: $5LB) is screaming “buy low, sell to the moon” vibes. This isn’t your average pump-and-dump – they’ve got real tech, clinical wins, and a pipeline that’s heating up. Let me break it down before it pops off.
Quick Rundown: Who TF Are They?
• Clinical-stage biopharma focused on immunotherapy vaccines for cancer and infectious diseases.
• Their secret sauce? The DPX™ platform – a lipid-in-oil delivery system that’s like a turbocharger for immune responses. It’s got over 120 patents, proven safe in Phase 1/2 trials, and works with peptides, mRNA, proteins… basically anything to supercharge vaccines without nasty side effects.
• Acquired IMV Inc. last year, beefing up their ovarian cancer pipeline and global reach.
Recent Wins That Have Me Hyped:
• Positive Phase 1 Results: Their lead candidate, Maveropepimut-S (MVP-S), crushed it in HR+/HER2- breast cancer – combined with chemo, it showed strong immune responses and tumor shrinkage. In ovarian cancer, 21% response rate and 63% disease control. DLBCL? Complete responses in half the patients when paired with Keytruda.
• 2025 Year in Review: Integrated DPX fully, built a killer team (including Stanford brains), and shifted to organic growth. CEO James Passin straight-up said 2026 could bring FIRST ROYALTY REVENUE from out-licensing and collabs. Out-licensing talks are ONGOING – think partnerships with big pharma like Pfizer or Moderna?
• Stock Moves: Did a 10:1 consolidation in Sept ’25 to clean up the share structure. Just upsized a private placement to $2M – cash for catalysts.
The Numbers Don’t Lie (But They’re Tiny – Perfect for Mooning):
• Current price: ~$0.17 USD / $0.23 CAD. Up 4.55% today, but down YTD? Yeah, -56%… that’s why it’s undervalued AF. Market cap? A measly $9M CAD. Tiny float means one good news drop and we’re talking 5-10x easy.
• Compare to peers: Biotech giants like Moderna ($MRNA) are trading at billions with similar tech. BioVaxys has Phase 2B data and is dirt cheap – room to run if they land a deal.
Risks? Yeah, It’s Biotech:
• Penny stock volatility – could go to zero if no deals materialize.
• Dilution from financings, but they’re small and strategic.
• Market’s been ignoring them post-consolidation, but Q1 2026 collabs could flip the script.
I’m in for a speculative bag because the upside is massive. If DPX™ gets licensed out, royalties could turn this into a multi-bagger. Who’s with me? Diamond hands or paper? Drop your DD, memes, or why I’m an idiot below. Let’s make this go viral – tag your biotech bros!
Not financial advice – DYOR, I’m just a ape with a keyboard. Positions: Long $BVAXF. 🚀🌕

$30 Jan16 MRNA calls.
Gearing up for the JPM conference on the 12th

Right on. ...going back to pharma (and the associated TAM), MRNA, Moderna, has been good to me in the last few months. They literally have cancer cures (amongst others) in the pipeline, and should outperform once the market starts pricing them as more than a COVID treatment. Similarly, NTRA, Natera, has some interesting DNA diagnostics. Getting a bit pricey, but I'm willing to at least hold until Druckmiller sells.

MRNA

MRNA looking hotter than two mice fucking in a wool sock

MRNA

Moderna MRNA

Huge volume spike on MRNA at 2 damn

Hey degenerates and biotech bulls! I’ve been digging into penny plays, and holy shit, BioVaxys Technology Corp. ($BVAXF OTCQB, $BIOV.CN CSE, FRA: $5LB) is screaming “buy low, sell to the moon” vibes. This isn’t your average pump-and-dump – they’ve got real tech, clinical wins, and a pipeline that’s heating up. Let me break it down before it pops off.
Quick Rundown: Who TF Are They?
• Clinical-stage biopharma focused on immunotherapy vaccines for cancer and infectious diseases.
• Their secret sauce? The DPX™ platform – a lipid-in-oil delivery system that’s like a turbocharger for immune responses. It’s got over 120 patents, proven safe in Phase 1/2 trials, and works with peptides, mRNA, proteins… basically anything to supercharge vaccines without nasty side effects.
• Acquired IMV Inc. last year, beefing up their ovarian cancer pipeline and global reach.
Recent Wins That Have Me Hyped:
• Positive Phase 1 Results: Their lead candidate, Maveropepimut-S (MVP-S), crushed it in HR+/HER2- breast cancer – combined with chemo, it showed strong immune responses and tumor shrinkage. In ovarian cancer, 21% response rate and 63% disease control. DLBCL? Complete responses in half the patients when paired with Keytruda.
• 2025 Year in Review: Integrated DPX fully, built a killer team (including Stanford brains), and shifted to organic growth. CEO James Passin straight-up said 2026 could bring FIRST ROYALTY REVENUE from out-licensing and collabs. Out-licensing talks are ONGOING – think partnerships with big pharma like Pfizer or Moderna?
• Stock Moves: Did a 10:1 consolidation in Sept ’25 to clean up the share structure. Just upsized a private placement to $2M – cash for catalysts.
The Numbers Don’t Lie (But They’re Tiny – Perfect for Mooning):
• Current price: ~$0.17 USD / $0.23 CAD. Up 4.55% today, but down YTD? Yeah, -56%… that’s why it’s undervalued AF. Market cap? A measly $9M CAD. Tiny float means one good news drop and we’re talking 5-10x easy.
• Compare to peers: Biotech giants like Moderna ($MRNA) are trading at billions with similar tech. BioVaxys has Phase 2B data and is dirt cheap – room to run if they land a deal.
Risks? Yeah, It’s Biotech:
• Penny stock volatility – could go to zero if no deals materialize.
• Dilution from financings, but they’re small and strategic.
• Market’s been ignoring them post-consolidation, but Q1 2026 collabs could flip the script.
I’m in for a speculative bag because the upside is massive. If DPX™ gets licensed out, royalties could turn this into a multi-bagger. Who’s with me? Diamond hands or paper? Drop your DD, memes, or why I’m an idiot below. Let’s make this go viral – tag your biotech bros!
Not financial advice – DYOR, I’m just a ape with a keyboard. Positions: Long $BVAXF. 🚀🌕

$30 Jan16 MRNA calls.
Gearing up for the JPM conference on the 12th

**Buy Now:** BRKR, LUNR, NEO, PALI, RDZN, SIDU, SIFY, STRO, TMQ
**Stocks to sell now:** 
**Recent Buys:** 
**Recent Sells:**  
**Close to Buy Triggers:**  ABAT, ACLS, AEVA, AMPH, APLS, ARCB, ASH, AUTL, AVY, BDSX, BEEM, BTAI, BURU, CBLL, CGTX, CMCO, DLHC, DSX, EGY, EHTH, ELBM, ELV, EVAX, EXPO, FATE, FEAM, FLXS, GILT, GWH, HOFT, HOUR, HTLD, HYPD, ICFI, IDAI, INO, INSM, JACK, LIDR, MRNA, NEOG, NET, NKTX, OLN, PATH, POWL, PRIM, QBTS, QMCO, REZI, SAIA, SBDS, SEED, SERV, SMHI, SNAP, SNBR, SPCE, THAR, TECX, TGT, TXG, UAVS, VRA, VREX, XNCR
**Current model owned stocks (stop sell price):**
**Updated (stop sell) orders calculated from technical analysis model output.**
BIIB (157.90), CRS (291.73), CW (526.74), DIBS (5.11), ESLT (497.54), ILMN (116.36), IRWD (3.12), LITE (356.33), MRK (90.47), ONTO (149.28), ORKA (27.27), PACS (30.96), PEPG (5.23), REGN (668.58), RLMD (3.67), ROK (363.90), RPTX (1.98), SVRA (5.50), SHIP (8.61), STTK (36.99), TCMD (24.04), TENX (10.31), UTHR (445.47), VALE (11.74), ZEUS (35.99)
Quantity of current Holdings:      26 stocks (26% equity)
New Sells                                                            
New Buys                                            9
New Quantity of Stocks:                 35
**Market Timing Model Status Update**    **Green.**  For accounts that can only invest in equity index funds, recommended position is 100% equity index.
Happy Investing,
Ludicrous Returns

If you bought MRNA after the first COVID vaccine was released to the general public, you would be down about 75%.
If you bought Zoom in March of 2020, you would be down about 50%.

Q for you then with your experience.
Ive been trading and investing for 15ish years.
In my experience sometimes the easiest most obvious big trend, trades really do work quite well.
For example, you could buy AAPL in '15 on a couple qs of slowing iPhone sales AFTER buffet bought it and showed up on the 13s.
You could buy MRNA and BioNTech AFTER we knew the vax was gonna work and still make a huge return.
Same for WFH stocks like zoom after it was clear WFH was gonna be a thing
The travel names when it was already apparent people were booking trips again
NVDA , AFTER chatGPT came out and AI was the hot thing.
LLY well after hundreds of articles and everyone plus their sister on GLP1
Euro weapons companies well into Ukraine war and re-arming under way.
So this trade is a simple one, yes, but does HAL and VLO make sense even if it's kinda obvious and consensus?